STOCK TITAN

Mirum Pharmaceuticals director exercises 14,167 options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) director Laura Brege exercised 14,167 fully vested options on November 11, 2026, at $16.71 per share, acquiring 14,167 common shares. She sold 10,907 shares at a weighted average of $94.05 per share and 3,260 shares at a weighted average of $94.74 per share. The transactions were not reported as made under a Rule 10b5-1 plan.

Insider Brege Laura
Role Director
Sold 14,167 shs ($1.33M)
Approx. gross sale proceeds $1.33M
Approx. exercise cost $237K
Approx. pre-tax spread $1.10M
Type Security Shares Price Value
Exercise Stock Option (right to buy) F3 14,167 $0.00 $0.00
Exercise Common Stock 14,167 $16.71 $237K
Sale Common Stock F1 10,907 $94.05 $1.03M
Sale Common Stock F2 3,260 $94.74 $309K
Holdings After Transaction: Stock Option (right to buy) — 0 options (Direct); Common Stock — 15,703 shares (Direct)
Footnotes (3)
  1. F1. The weighted average sale price for the transaction reported was $94.05, and the range of prices were between $93.63 and $94.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  2. F2. The weighted average sale price for the transaction reported was $94.74, and the range of prices were between $94.635 and $94.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  3. F3. The stock option is fully vested.
Options exercised 14,167 options November 11, 2026
Option exercise price $16.71 per share 14,167 options exercised on November 11, 2026
Shares sold, first transaction 10,907 shares November 11, 2026; weighted-average sale price was $94.05 per share
Weighted-average sale price, first transaction $94.05 per share 10,907-share sale on November 11, 2026
Shares sold, second transaction 3,260 shares November 11, 2026; weighted-average sale price was $94.74 per share
Weighted-average sale price, second transaction $94.74 per share 3,260-share sale on November 11, 2026
weighted average sale price financial
"the reported 10,907-share sale"
fully vested financial
"the 14,167-share option exercise"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MIRM shares did director Laura Brege sell, and at what prices?

Laura Brege sold 10,907 shares at a weighted average of $94.05 per share and 3,260 shares at a weighted average of $94.74 per share on November 11, 2026. The respective sale-price ranges were $93.63 to $94.61 and $94.635 to $94.91 per share. The transactions were not reported as made under a Rule 10b5-1 plan.

How many options did MIRM director Laura Brege exercise, and at what price?

Laura Brege exercised 14,167 fully vested options at $16.71 per share on November 11, 2026, acquiring 14,167 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brege Laura

(Last)(First)(Middle)
C/O MIRUM PHARMACEUTICALS, INC.
989 E HILLSDALE BLVD., SUITE 300

(Street)
FOSTER CITY CALIFORNIA 94404

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/11/2026M14,167A$16.7129,870D
Common Stock11/11/2026S10,907D$94.05(1)18,963D
Common Stock11/11/2026S3,260D$94.74(2)15,703D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$16.7111/11/2026M14,167 (3)06/10/2030Common Stock14,167$00D
Explanation of Responses:
1. The weighted average sale price for the transaction reported was $94.05, and the range of prices were between $93.63 and $94.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
2. The weighted average sale price for the transaction reported was $94.74, and the range of prices were between $94.635 and $94.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. The stock option is fully vested.
/s/ Judit Ryvkin, Attorney-in-Fact11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading